Kambani yehunyanzvi hwekurapa yakatarisana nekugadzira matekinoroji ekutanga kuongororwa kenza, nhasi yazivisa mitsva yekutsvaga mhinduro. Ongororo yekiriniki yegomarara rechiropa yakaratidza kugona kukuru kweLAM's itsva DNA methylation-based biomarker kuona hepatocellular carcinoma (HCC) Kunzwa kwekuziva ndeye 95% uye iyo chaiyo i97.5%.
Muchidzidzo ichi, zvidzidzo zvezvikamu zve130 zvakaunganidzwa, kusanganisira: 60 zvidzidzo zvakaonekwa kuti zvine hepatocellular carcinoma (danho I kusvika kuIV), zvidzidzo zve30 zvisina chirwere chechiropa, 10 Zvidzidzo zvakaonekwa kuti zvine chirwere chechiropa chechiropa uye zvidzidzo zve30 zvakaonekwa kuti zvine kenza yemazamu, kenza yakaoma. kana kenza yemapapu. DNA yakatorwa kubva mumuenzaniso, iyo DNA yakashandurwa nebisulfite, uye DNA methylation yakaverengerwa pachishandiswa IvyGene chikuva. Mushure mekupedza kuunganidza data uye ongororo yemasampuli ese, pofomadza masampula kuti uverenge kuita kwebvunzo.
A total of 57 of the 60 samples taken from patients with hepatocellular carcinoma were correctly identified, with an overall calculated sensitivity of 95%. The sensitivity difference between detecting stage I and stage IV hepatocellular carcinoma was small (range 89% to 100%). Of the samples taken from cancer patients other than liver cancer, 90% of breast cancer samples, 80% of kenza yakajeka samples, and 90% of lung cancer samples were correctly identified as non-liver cancer, and the total calculated specificity was 87%.
